The American Cancer Society completed a series of systematic reviews and found that PSA screening for any prostate cancer with a cutoff of 4.0 ng/mL resulted in 21% of screening tests that identified prostate cancer being truly positive (sensitivity) and 91% of screening tests that did not identify prostate cancer being truly negative (specificity) [79]. This evidence concerns the gene KLK3 and prostate cancer.